Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma

Endocrine Pathology

Volumn 24, Issue 4, 2013, Pages 169-176

  Shin, Dong Yeob ^a   Kim, Kwang Joon ^a,b   Ku, Cheol Ryong ^a   Lee, Mi Kyung ^c   Jee, Soo Il ^c   Chung, Woong Youn ^a   Lee, Eun Jig ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c National Health Insurance Corporation   (South Korea)

Author keywords

Chemokine Receptor; CXCR4; Immunohistochemistry; Papillary Thyroid Carcinoma; Tissue Microarray

Indexed keywords

CHEMOKINE RECEPTOR CXCR4;

ADULT; ARTICLE; CANCER MORPHOLOGY; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; THYROID PAPILLARY CARCINOMA; TUMOR VOLUME;

ADULT; CARCINOMA, PAPILLARY; CARCINOMA, PAPILLARY, FOLLICULAR; FEMALE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CXCR4; THYROID GLAND; THYROID NEOPLASMS;

EID: 84888199077     PISSN: 10463976     EISSN: 15590097     Source Type: Journal    
DOI: 10.1007/s12022-013-9259-6     Document Type: Article

References (34)

1. Sherman SI. Thyroid carcinoma. Lancet 361:501-11, 2003.
2. Arturi F, Russo D, Giuffrida D, et al. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. J Clin Endocrinol Metab 82:1638-41, 1997.
3. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid - prognostic significance of lymph node metastasis and multifocality. Cancer 98:31-40, 2003.
4. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery 131:249-56, 2002.
5. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 8:148-56, 2007.
6. Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol 18:217-42, 2000.
7. Zlotnik A. Chemokines and cancer. Int J Cancer 119:2026-9, 2006.
8. Kim CH, Broxmeyer HE. SLC/exodus2/6Ckine/TCA4 induces chemotaxis of hematopoietic progenitor cells: differential activity of ligands of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor proliferation. J Leukoc Biol 66:455-61, 1999.
9. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14:171-9, 2004.
10. Aust G, Steinert M, Kiessling S, Kamprad M, Simchen C. Reduced expression of stromal-derived factor 1 in autonomous thyroid adenomas and its regulation in thyroid-derived cells. J Clin Endocrinol Metab 86:3368-76, 2001.
11. Castellone MD, Guarino V, De Falco V, et al. Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas. Oncogene 23:5958-67, 2004.
12. De Falco V, Guarino V, Avilla E, et al. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer. Cancer Res 67:11821-9, 2007.
13. Hwang JH, Hwang JH, Chung HK, et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:408-16, 2003.
14. González HE, Leiva A, Tobar H, et al. Altered chemokine receptor expression in papillary thyroid cancer. Thyroid 19:957-65, 2009.
15. Wagner PL, Moo T-A, Arora N, et al. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma. Ann Surg Oncol 15:2833-41, 2008.
16. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410:50-6, 2001.
17. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335-48, 2005.
18. Borrello MG, Alberti L, Fischer A, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci USA 102:14825-30, 2005.
19. Yasuoka H, Kodama R, Hirokawa M, et al. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis. BMC Cancer 8:274, 2008.
20. Burningham AR, Krishnan J, Davidson BJ, Ringel MD, Burman KD. Papillary and follicular variant of papillary carcinoma of the thyroid: initial presentation and response to therapy. Otolaryngol Head Neck Surg 132:840-4, 2005.
21. Passler C, Prager G, Scheuba C, et al. Follicular variant of papillary thyroid carcinoma: a long-term follow-up. Arch Surg 138:1362-6, 2003.
22. Zidan J, Karen D, Stein M, Rosenblatt E, Basher W, Kuten A. Pure versus follicular variant of papillary thyroid carcinoma: clinical features, prognostic factors, treatment, and survival. Cancer 97:1181-5, 2003.
23. Chow SM, Chan JK, Law SC, et al. Diffuse sclerosing variant of papillary thyroid carcinoma - clinical features and outcome. Eur J Surg Oncol 29:446-9, 2003.
24. Vickery AL, Jr., Carcangiu ML, Johannessen JV, Sobrinho-Simoes M. Papillary carcinoma. Semin Diagn Pathol 2:90-100, 1985.
25. Albareda M, Puig-Domingo M, Wengrowicz S, et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 8:385-91, 1998.
26. Carcangiu ML, Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 13:1041-9, 1989.
27. Koo JS, Hong S, Park CS. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid 19:1225-31, 2009.
28. Ito Y, Hirokawa M, Fukushima M, et al. Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan. World J Surg 32:1535-43; discussion 44-5, 2008.
29. Volante M, Collini P, Nikiforov YE, et al. Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol 31:1256-64, 2007.
30. He X, Wei Q, Zhang X, et al. Immunohistochemical expression of CXCR4 in thyroid carcinomas and thyroid benign lesions. Pathol Res Pract 206:712-5, 2010.
31. Nikiforova MN, Kimura et, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-404, 2003.
32. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am J Clin Pathol 120:71-7, 2003.
33. Lam AK, Lo CY. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol 13:176-81, 2006.
34. Thompson LD, Wieneke JA, Heffess CS. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 16:331-48, 2005.